04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD5 molecule-like (AIM; CD5L)

Renal disease INDICATION: Renal damage Cell culture and mouse studies suggest AIM could help treat acute kidney injury (AKI). In a mouse model of severe AKI, AIM decreased acute tubular necrosis and accumulation of intratubular debris in...
08:00 , Feb 25, 2016 |  BC Innovations  |  Translation in Brief

AIMing high

Clearing necrotic debris is a critical step in overcoming acute kidney injury (AKI), but failing to turn off the phagocyte response can lead to renal fibrosis in the long term. A Japanese group has shown...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Metabolic disease; diabetes CD5 molecule-like (CD5L; AIM) Studies in mice suggest antagonizing CD5L could help prevent progression...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); hairy cell leukemia CD160; CD23; CD5 Human studies suggest CD160 expression could help...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity CD5 molecule-like (CD5L; AIM) In vitro and mouse studies suggest that CD5L could help prevent...
07:00 , Jun 1, 2009 |  BioCentury  |  Regulation

Accelerate, or not

Arzerra ofatumumab from Genmab A/S and partner GlaxoSmithKline plc would appear to be a classic example of why accelerated approval was created. With last Friday's 10-3 vote by the Oncologic Drugs Advisory Committee to recommend...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease ...
07:00 , Oct 30, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Transplantation ...
07:00 , Apr 19, 2004 |  BioCentury  |  Strategy

Making the 'make' decision

Drug discovery and development is like the portion of an iceberg that is above water: visible and dramatic. Manufacturing is like the portion that is under water: out of sight and often out of mind....